References
- Oudinet C, Braikia FZ, Dauba A, et al. Mechanism and regulation of class switch recombination by IgH transcriptional control elements. Adv Immunol. 2020;147:89–137.
- Ghazzaui N, Issaoui H, Ferrad M, et al. Eμ and 3'RR transcriptional enhancers of the IgH locus cooperate to promote c-myc-induced mature B-cell lymphomas. Blood Adv. 2020;4(1):28–39.
- Saintamand A, Saad F, Denizot Y. 3'RR targeting in lymphomagenesis: a promising strategy? Cell Cycle. 2015;14(6):789–790.
- Saintamand A, Vincent-Fabert C, Garot A, et al. Deciphering the importance of the palindromic architecture of the immunoglobulin heavy-chain 3' regulatory region. Nat Commun. 2016;7:10730.
- Le Noir S, Boyer F, Lecardeur S, et al. Functional anatomy of the immunoglobulin heavy chain 3' super-enhancer needs not only core enhancer elements but also their unique DNA context. Nucleic Acids Res. 2017;45(10):5829–5837.
- Saintamand A, Rouaud P, Saad F, et al. Elucidation of IgH 3' region regulatory role during class switch recombination via germline deletion. Nat Commun. 2015;6:7084.
- Saintamand A, Vincent-Fabert C, Marquet M, et al. Eµ and 3'RR IgH enhancers show hierarchic unilateral dependence in mature B-cells. Sci Rep. 2017;7(1):442.
- Lu ZP, Ju ZL, Shi GY, et al. Histone deacetylase inhibitor trichostatin a reduces anti-DNA autoantibody production and represses IgH gene transcription. Biochem Biophys Res Commun. 2005;330(1):204–209.
- Ferrad M, Ghazzaui N, Issaoui H, et al. Mouse models of c-myc deregulation driven by IgH locus enhancers as models of B-cell lymphomagenesis. Front Immunol. 2020;11:1564.
- D'Addabbo P, Scascitelli M, Giambra V, et al. Position and sequence conservation in amniota of polymorphic enhancer HS1.2 within the palindrome of IgH 3'Regulatory Region. BMC Evol Biol. 2011;11:71.
- Nambu Y, Sugai M, Gonda H, et al. Transcription-coupled events associating with immunoglobulin switch region chromatin. Science. 2003;302(5653):2137–2140.
- Hu HM, Kanda K, Zhang L, et al. Activation of the c-myc P1 promoter in Burkitt's lymphoma by the hs3 immunoglobulin heavy-chain gene enhancer . Leukemia. 2007;21(4):747–753.
- Waibel M, Christiansen AJ, Hibbs ML, et al. Manipulation of B-cell responses with histone deacetylase inhibitors. Nat Comm. 2015;6:6838.
- Lindström MS, Wiman KG. Role of genetic and epigenetic changes in burkitt lymphoma. Semin Cancer Biol. 2002;12(5):381–387.
- Sborov DW, Canella A, Hade EM, et al. A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas. Leuk Lymphoma. 2017;58(10):1218–2310.